The cost of treating sickle cell anemia in India is on the verge of crashing. Hydroxyurea, a line of treatment, will now cost less than 1% of current import price. Healthcare costs are a source of economic pressure on most Indian families. It’s led to govt intervention to improve access to medicines and provide insurance cover to cover emergencies.